Abstract: Poster Presentations |

Safety and Efficacy of Gemifloxacin Compared to High Dose Amoxicillin/Clavulanate for the Treatment of Community-Acquired Pneumonia (CAP) of Suspected Pneumococcal Origin FREE TO VIEW

Glenn S. Tillotson, MS; Thomas File, MD*; Lionel Mandell, MD
Author and Funding Information

Northeastern Ohio Universities College of Medicine, Rootstown, OH


Chest. 2004;126(4_MeetingAbstracts):847S. doi:10.1378/chest.126.4_MeetingAbstracts.847S-b
Text Size: A A A
Published online


PURPOSE:  To compare the safety and efficacy of gemifloxacin to high dose amoxicillin/clavulanate (amox/clav) for the treatment of CAP of suspected pneumococcal origin (based on clinical characteristics including gram stain findings of sputum).

METHODS:  Randomized, multicenter, double-blind, double-dummy study. 324 patients with CAP received oral gemifloxacin 320mg once daily for 7 days or oral amox/clav 1g/125mg 3 times daily for 10 days. Outcome measures were clinical, bacteriological, and radiological responses at the end of therapy (EOT; Day 12–14) and follow-up (FU; Day 24–30).

RESULTS:  In 228 Per Protocol (PP) patients, clinical resolution at FU was 88.7% for gemifloxacin and 87.6% for amox/clav [95% CI -7.3,9.5]. Clinical resolution at EOT was 95.3% for gemifloxacin vs. 90.1% for amox/clav.[ 95%CI, -1.2, 11.7] Bacteriologic responses for PP patients at EOT were 96.3% for 7-day gemifloxacin and 91.8% for the amox/clav group [95%CI, -4.7, 13.6], and at FU were 87.2% for gemifloxacin and 89.1% for the amox/clav group [95%CI -15.0, 11.2]. Gemifloxacin eradicated 95.7% (22/23) and amox/clav eradicated 100% (21/21) of Streptococcus pneumoniae including penicillin- and macrolide-resistant strains. Radiological responses at EOT were 89.1% for gemifloxacin and 87.6% for amox/clav. The most frequently reported drug-related events were in the gemifloxacin group, diarrhea (6.0%) and rash (3.0%) and in the amox/clav group, diarrhea (11.1%) and fungal infection, vaginitis and vomiting (each 2.0%). There were statistically fewer withdrawals due to lack of therapeutic effect in the gemifloxacin group (2/33; 6%) vs the amox/clav cohort (9/33; 27%), (95% CI -8.8;0.6; p=0.03).

CONCLUSION:  Gemifloxacin 320 mg once daily for 7 days was clinically, bacteriologically, and radiologically as effective as 10 days of amox/clav 1g/125mg 3 times daily for the treatment of suspected pneumococcal CAP.

CLINICAL IMPLICATIONS:  Gemifloxacin represents a valuable addition to the therapeutic options to treat CAP.

DISCLOSURE:  T. File, None.

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543